Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
January 12, 2021 03:30 ET
|
Helsinn Healthcare S.A.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss...
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI)
September 23, 2020 04:43 ET
|
Helsinn Healthcare S.A.
Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI) Lugano, Switzerland,...
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US
August 20, 2020 09:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building...
3B Future Health Fund announces new investment in iOnctura
July 14, 2020 03:00 ET
|
Helsinn Healthcare S.A.
3B Future Health Fund announces new investment in iOnctura MONACO, PRINCIPALITY OF MONACO, July 14, 2020: 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today...
Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund
June 10, 2020 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund Lugano, Switzerland, June 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer...
Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron)
March 23, 2020 06:00 ET
|
Helsinn Healthcare S.A.
Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron) Lugano, Switzerland, March 23, 2020 – Helsinn, the Swiss pharmaceutical group focused on building...
Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020
August 29, 2019 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020 The Award recognizes Patient...
Helsinn Investment Fund Announces First Exit
July 15, 2019 10:05 ET
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Announces First Exit Luxembourg, July 15, 2019 – Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient...
Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association
May 07, 2019 11:19 ET
|
Helsinn Healthcare S.A.
Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association Switzerland, May 7, 2019: Helsinn, a Swiss pharmaceutical group focused on building quality cancer care...
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care
January 31, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care Lugano, Switzerland, January 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on...